<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03264794</url>
  </required_header>
  <id_info>
    <org_study_id>CTTQ-20161017</org_study_id>
    <nct_id>NCT03264794</nct_id>
  </id_info>
  <brief_title>the Clinical Trial of Gefitinib(Non - Small Cell Lung Cancer)</brief_title>
  <official_title>Evaluation of the Efficacy of Domestic Gefitinib Tablets in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients Using a Multicenter, Randomized, Positive Drug Gefitinib Pharmacodynamics and Pharmacodynamics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Famous Medical Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Famous Medical Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Gefitinib CTTQ production gefitinib and erlotinib sheet AstraZeneca imatinib sheet&#xD;
           (trade name: Iressa ®) comparison, human pharmacokinetics and relative bioavailability&#xD;
           of comparative studies which examine people in vivo pharmacokinetic behavior, provide&#xD;
           the basis for clinical use.&#xD;
&#xD;
        2. Evaluation CTTQ gefitinib imatinib sheet production efficacy and safety of Chinese&#xD;
           patients with locally advanced or metastatic non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2017</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gefitinib plasma concentration</measure>
    <time_frame>0hour before administration and 1, 2, 3, 4, 5, 6, 7, 8,9,13,24,48,72,120,168 16 hour time points after administration</time_frame>
    <description>After the use of gefitinib to reach the highest plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax time</measure>
    <time_frame>0hour before administration and 1, 2, 3, 4, 5, 6, 7, 8,9,13,24,48,72,120,168 16 hour time points after administration</time_frame>
    <description>Taking the time required for the concentration of gefitinib to reach the peak</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>0hour before administration and 1, 2, 3, 4, 5, 6, 7, 8,9,13,24,48,72,120,168 16 hour time points after administration</time_frame>
    <description>The area between the axis of the coordinate and the time drug concentration curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t 1/2</measure>
    <time_frame>0hour before administration and 1, 2, 3, 4, 5, 6, 7, 8,9,13,24,48,72,120,168 16 hour time points after administration</time_frame>
    <description>The time required for gefitinib to decrease by half the highest concentration in plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>F</measure>
    <time_frame>0hour before administration and 1, 2, 3, 4, 5, 6, 7, 8,9,13,24,48,72,120,168 16 hour time points after administration</time_frame>
    <description>Gefitinib absorbs the relative amount of blood into the cycle</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>trial group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gefitinib tablets (CTTQ），First medication.From the 8th day of the experiment, treated with Gefitinib Tab（CTTQ）</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gefitinib tablets (Yi Ruisha），First medication.From the 8th day of the experiment, treated with Gefitinib Tab（CTTQ）</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefitinib Tab （CTTQ），First medication；Gefitinib Tab （CTTQ），From the 8th day of trial</intervention_name>
    <description>Gefitinib Tab （CTTQ），First medication,250mg；</description>
    <arm_group_label>trial group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefitinib tablets (Yi Ruisha），First medication</intervention_name>
    <description>Gefitinib tablets (Yi Ruisha），First medication,250mg；</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefitinib Tab 250 MG（CTTQ），From the 8th day of trial.</intervention_name>
    <description>From the 8th day of the experiment, two groups of subjects were treated with Gefitinib（CTTQ）</description>
    <arm_group_label>control group</arm_group_label>
    <arm_group_label>trial group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients volunteered to participate in this study, signed informed consent;&#xD;
&#xD;
          2. ≥18 years old; ECOG PS score: 0 ~ 1; expected survival period of more than 3 months;&#xD;
&#xD;
          3. patients with locally advanced or metastatic non-small cell lung cancer diagnosed by&#xD;
             histology or cytology, who can not receive radical surgery or radiotherapy; patients&#xD;
             with measurable lesions(according to RECIST criteria);&#xD;
&#xD;
          4. Detection of EGFR-positive exon 19 deletion or exon 21 (L858R) mutation was performed&#xD;
             by providing a detectable specimen (tissue or cancerous pleural effusion) prior to&#xD;
             enrollment;&#xD;
&#xD;
          5. The main organ function within 7 days before treatment, meet the following criteria:&#xD;
&#xD;
        (1) blood routine examination criteria (14 days without blood transfusion): A) hemoglobin≥&#xD;
        90g / L; B) neutrophil absolute ≥ 1.5 × 109 / L; C) platelet ≥80 × 109 / L (2) biochemical&#xD;
        tests to meet the following criteria: A) total bilirubin ≤ 1.5 times the upper limit of&#xD;
        normal (ULN); B) alanine aminotransferase and aspartate aminotransferase AST ≤ 2.5ULN, such&#xD;
        as liver metastasis, ALT and AST ≤ 5ULN; C) serum creatinine ≤ 1.5ULN or creatinine&#xD;
        clearance ≥ 60ml / min; (3) Doppler ultrasound evaluation: left ventricular ejection&#xD;
        fraction (LVEF) ≥ normal low (50%).&#xD;
&#xD;
        6.Women of childbearing age should agree that contraceptive measures (such as intrauterine&#xD;
        devices, birth control pills or condoms) must be used within the study period and within 6&#xD;
        months after the end of the study; serum or urine pregnancy test is negative within 7 days&#xD;
        prior to enrollment, And must be non-lactating patients; men should agree to patients who&#xD;
        have contraceptive use during the study period and six months after the end of the study&#xD;
        period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. patients who have previously used EGFR-TKI drugs;&#xD;
&#xD;
          2. small cell lung cancer (including small cell carcinoma and non-small cell carcinoma&#xD;
             mixed lung cancer);&#xD;
&#xD;
          3. central type, with empty lung squamous cell carcinoma, or with non-small cell lung&#xD;
             cancer with hemoptysis (&gt; 50 ml / day) 4.5 years or at the same time with other&#xD;
             malignancies, cured cervical carcinoma in situ, non-melanoma skin cancer and&#xD;
             superficial bladder tumor except [Ta (non-invasive tumor), Tis (carcinoma in situ )&#xD;
             And T1 (tumor infiltrating basement membrane)];&#xD;
&#xD;
        5.Whole-body antitumor therapy was planned within 4 weeks prior to randomization or during&#xD;
        the course of this study, including cytotoxic therapy, signal transduction inhibitors,&#xD;
        immunotherapy (or use of mitogen at 6 weeks prior to administration of the test drug) C);&#xD;
        6.patients with symptomatic or unstable brain metastases; 7.patients with any severe and /&#xD;
        or uncontrolled disease, including: A) cirrhosis, acute or active hepatitis; B) history of&#xD;
        immunodeficiency, including HIV-positive or other acquired, congenital immunodeficiency&#xD;
        disease, or history of organ transplantation; C) patients with seizures and who need&#xD;
        treatment; 8.active or uncontrollable serious infection (≥CTC AE Level 2 infection); 9.with&#xD;
        a history of mental illness and can not quit or have mental disorders; 10.participated in&#xD;
        other anti-tumor drug clinical trials within four weeks; 11.According to the judge's&#xD;
        judgment, there is an impact on the absorption of oral drugs or serious harm to the safety&#xD;
        of patients is not suitable for participation in the study of the situation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>July 3, 2017</study_first_submitted>
  <study_first_submitted_qc>August 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2017</study_first_posted>
  <last_update_submitted>August 28, 2017</last_update_submitted>
  <last_update_submitted_qc>August 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

